JD Health International Inc
HKEX:6618
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.82
39.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
JD Health International Inc
JD Health International Inc
Cost of Revenue
JD Health International Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
JD Health International Inc
HKEX:6618
|
Cost of Revenue
-¥41.7B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Vipshop Holdings Ltd
NYSE:VIPS
|
Cost of Revenue
-¥83.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-20%
|
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Cost of Revenue
-¥594.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-42%
|
|
|
Pinduoduo Inc
NASDAQ:PDD
|
Cost of Revenue
-¥141.2B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
N/A
|
|
|
Meituan
HKEX:3690
|
Cost of Revenue
-¥194.1B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
JD.Com Inc
HKEX:9618
|
Cost of Revenue
-¥943.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-27%
|
|
JD Health International Inc
Glance View
JD Health International Inc. is not just another player in the rapidly evolving health and wellness landscape; it stands out as a pioneering force driven by technology and innovation. Established in 2015 as a subsidiary of JD.com, one of China's largest e-commerce platforms, JD Health is leveraging its parent company's robust logistics network and cutting-edge technology to reshape healthcare access in China. The company focuses on providing a seamless online healthcare experience, offering a diverse range of services that include online pharmacy sales, health consultations, and prescription management. With growing consumer demand for digital health solutions, JD Health is capitalizing on the shift toward telemedicine and remote healthcare services, positioning itself as a leader in this promising market. For investors, JD Health International Inc. represents a compelling opportunity rooted in strong growth prospects and market leadership. As digital health continues to gain traction, the company has demonstrated impressive revenue growth, propelled by its extensive user base and innovative service offerings. JD Health’s commitment to leveraging advanced technologies like artificial intelligence and big data analytics not only enhances operational efficiency but also improves customer satisfaction and outcomes. Coupled with a solid financial backing from JD.com's established marketplace and logistics capabilities, JD Health is strategically poised to expand its footprint in both urban and rural areas, ultimately aiming to bridge the healthcare accessibility gap in China. As the company navigates the dynamic healthcare environment, its growth trajectory suggests a sustainable business model with substantial long-term value.
See Also
What is JD Health International Inc's Cost of Revenue?
Cost of Revenue
-41.7B
CNY
Based on the financial report for Dec 31, 2023, JD Health International Inc's Cost of Revenue amounts to -41.7B CNY.
What is JD Health International Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-46%
Over the last year, the Cost of Revenue growth was -13%. The average annual Cost of Revenue growth rates for JD Health International Inc have been -42% over the past three years , -46% over the past five years .
You don't have any saved screeners yet
